INTRODUCTION
Gastric carcinoma is now reported to be the second most commonly diagnosed malignancy (after lung carcinoma in men and breast carcinoma in women) in Turkey.' Unfortunately, the rate of early diagnosis of gastric cancer in our country is very low « 5%). Patients usually have stage III or IV carcinomas at the time of diagnosis."
Gastric adenocarcinomas are generally incurable and aggressive tumours are associated with poor prognosis.l" Even when complete surgical excision is possible, the incidence of local recurrence and disseminated disease remains high." In view of the late diagnosis of gastric carcinoma in Turkey, treatment by systematic chemotherapy has been advocated, but the results of chemotherapy have been disappointing.
Multidrug resistance (mdr-I gene product) synthesis is correlated with increased amounts of P-glycoprotein production. P-glycoprotein plays a role in the development of drug resistance by affecting the active transport of chemotherapeutic agents and the energy-dependent transmembrane excretion pump in the cells." 7 The expression of this I70-kDa transmembrane protein can be shown by an immunohistochemical technique."
In this study, we investigated the expression of P-glycoprotein and its relationship with multiple prognostic factors in gastric carcinoma in Turkey.
MATERIALS AND METHODS

SPECIMENS
The study involved 55 patients who had had a diagnosis of gastric carcinoma from examination of surgical specimens. All patients had been diagnosed in our Department of Gastroenterology and underwent surgery in the Department of General Surgery. The tumour 80 histopathological subtypes were determined by Lauren's classification." The stage of disease was described by the TNM classification."} None of the patients had chemotherapy. Tumour specimens were obtained from surgical resection of primary tumours of gastric carcinomas.
DETECTION OF MDR-l EXPRESSION
For immunohistochemical studies, 5-p.m sections were cut from formalin-fixed, paraffin-embedded tissues. Tissue samples were deparaffinized in xylene after heating, rehydrated through graded alcohol, and washed in 3% hydrogen peroxide solution for 5 min.
The specific monoclonal mouse anti-P-glycoprotein (DAKO, M 3522) was used for immunohistochemical staining. The tumour grade, tumour type, extent of lymphatic, vascular and perineural invasion, necrosis, desmoplastic reaction and clinical characteristics of each case were evaluated and scored (between 0 and 3), and the relationship between the MDR-I expression (as indicated by the level of tumour staining) and clinicopathological factors was investigated.
STATISTICAL ANALYSIS
Differences between groups with different levels of MDR-I positivity were analysed statistically with regard to clinicopathological parameters, by the Mann-Whitney V-test and the xl-test using the SPSS program. P-values < 0.05 were considered to be statistically significant. 
RESULTS
Between 1996 and 1998. 37 men and 18 women (mean ± SE age, 55 ± 2 years; range, 20 -75 years) were included in the study.
Of the 55 gastric carcinomas we examined. seven (13%) did not show any immunoreactivity for P-glycoprotein and 48 (87%) had positive staining for P-glycoprotein at different levels ( Fig. 1) .
None of the clinicopathological factors. including the histopathological type of tumour or the extent of the diseases. correlated with the expression of P-glycoprotein (Table 1) .
Immunostaining for P-glycoprotein was positive more frequently in male patients. but this association was not statistically significant. Elevated levels of P-glycoprotein were also not associated with the anatomical site (cardia, 14 patients; fundus, five patients; corpus, 11 patients; antrum. 25 patients).
There were no statistically significant differences among MDR-l-positive and MDR-l-negative groups with regard to histological subtype of tumour. grade of disease. level of lymphatic vascular or perineural invasion, necrosis or desmoplastic reaction (Table 1) .
In patients whose tumours contained (+++) positive P-glycoprotein. the probability of survival was significantly lower than in patients whose tumours contained less P-glycoprotein (P < 0.05).
DISCUSSION
Gastric carcinoma has been recognized as a leading cause of death from cancer in Turkey." Lack of early diagnosis reduces the chance of surgical therapy and only palliative surgery can be done. In view of this, chemotherapy is the only choice for patients diagnosed at a late stage, but unfortunately these patients are unresponsive to chemotherapy. Whether drug resistance plays a role in this low response to chemotherapy is a matter of question. Multidrug resistance (MDR) accompanies P-glycoprotein oversynthesis. P-glycoprotein affects transportation of chemotherapeutic agents from the cells and the transmembrane excretion pump, and plays a role in drug resistance."
Expression of MDR-1 and clinicopathological characteristics of patients who had undergone gastrectomy for gastric carcinoma
We used immunohistochemical methods 82 to examine paraffin-embedded tissue sections of gastric carcinoma for the presence of P-glycoprotein. The reliability of the monoclonal antibodies that we used (DAKO, M 3522) against P-glycoprotein has been investigated in some tumours. ll -D With the use of these antibodies, we were able to evaluate immunohistochemically both how representative a specimen was, and its P-glycoprotein status.
The biological significance and expression ofP-glycoprotein in gastric cancer have rarely been investigated." The largest series to date included 60 patients with gastric cancer." The MDR-1 expression rates, using an immunohistochemical staining method, have been reported to range from 16% to 36.8%. 16 In our series of 55 patients, P-glycoprotein expression was found to be rather high. Our study demonstrated expression of MDR-1 in 89% of the primary gastric carcinomas. This expression level is high compared with those reported in other studies in the literature." High levels of MDR-1 expression may be responsible for the unresponsiveness to chemotherapy in these patients.
A high level of P-glycoprotein in tumours was associated with a decreased probability of survival, but we did not find any meaningful relationship between any of the clinicopathological factors and MDR-1 expression.
From the results of this preliminary study, we assume that MDR-1 expression is high in gastric cancer patients in this part of Turkey. This high level of expression indicates that the response to therapy will be low, and also that chemotherapy may not be a good choice of treatment for our patients. At present in Turkey, only a small proportion of gastric cancers are diagnosed at an early stage, but we believe that early diagnosis would increase the chance of surgical therapy.
We did not observe an association between MDR-1 gene expression and lymphatic, vascular or perineural invasion, desmoplastic reaction, necrosis, or type or grade of tumour. In a recent study of gastro-oesophageal adenocarcinomas, no increase in expression of P-glycoprotein was seen in lymph-node or distant metastases." In colon carcinomas, however, expression of P-glycoprotein was related to local tumour aggressiveness and lymph-node metastasis."
It is unknown whether expression of the MDR-1 gene has any prognostic significance. An evaluation of MDR-1 gene expression is not usually used to make a prognosis for patients with gastric carcinomas. In our study, however, we found that there was an association between P-glycoprotein expression and prognosis: high MDR-1 expression (especially +++ positive) was associated with poor prognosis (mean ± SE survival, 13.8 ± 2.7 months; P < 0.05 versus all other P-glycoprotein groups).
The most important finding of this study is that P-glycoprotein expression is very high in gastric carcinomas in Turkey. These high levels of expression of P-glycoprotein indicate the presence of drug-resistant cells that make the tumours unresponsive to systemic chemotherapy. 
